PDA is Tackling the Data Integrity Topic

Richard M. Johnson
President & CEO
Parenteral Drug Association (PDA)
• A basic principle of assuring the quality of healthcare products is the review of data: by industry of data from their partners, of manufacturing and testing data by an independent quality function, and of all of this data by regulators who are responsible for monitoring the products for the public.

• The accuracy and trustworthiness of the data, the integrity of that data, must not be in question, or all of the checks and balances, control measures, and quality agreements will not be effective.
Key themes from PDA-FDA 2014 Brainstorming Meeting on Data Integrity

- Culture—quality and local -- issue is huge. Good quality culture can counterbalance weak systems. Culture can influence understanding or definition of “integrity”
- Data Integrity is a disease with a spectrum like cancer; proper diagnosis is needed to identify appropriate treatments.
- Data Integrity is really a design issue. Fear or desire to make a batch pass leads to DI problems. A lifecycle problem.
- All levels and parts of the organization need to understand importance of DI and their individual roles: C suite, IT, operator level, etc. First level supervision is key.
- Natural tendency to bias and assume a root cause rather than make a thorough analysis. Assumption the equipment is broken etc.
- Companies to consider whether rewards are based on outcomes or behaviors
Data Integrity: Increased Focus of Regulatory Agencies Worldwide

Increasing trend in Health Authority Observations and Actions related to Data Integrity.

- US FDA Warning Letters & Import Alerts
- EU Non Compliance Reports
- WHO Notices of Concern and De-certification

Data integrity refers to the quality and accuracy of data over the entire data lifecycle.

A = Attributable
L = Legible
C = Contemporaneous
O = Original
A = Accurate
Regulatory Guidance & Trends

Stay Current!

- MHRA Guidance, March 2015; Draft Revision, July 2016
- FDA Draft Guidance, April 2016
- WHO Annex 5, June 2016
- PIC/s Draft Guidance, August 2016
Regulatory Guidance & Trends

- Warning Letters/Untitled Letters
- FDA 483 Observations
- Import Alerts
- EU Non-Compliance Reports
- WHO De-Certification
High Quality Decisions Come From High Quality Data

Every Step has Data In and Data Out

Is this product safe and effective for the patient?
High Quality Decisions Come From High Quality Data

Is this product safe and effective for the patient?

- Operator Training Records
- Quality Control Checks
- Media Fill Results
- Raw Material Identity
- Filter Integrity Testing
- Potency Assay
- Particulate Inspection
- Equipment Cleaning Logs
- Preventive Maintenance
- Sterilization Cycle Validation
Examples of Data Integrity Problems

- Security Breaches of physical plant or information systems
- Site access without secure ID.
- Uncontrolled and unrecorded access to restricted rooms such as data centers, manufacturing suites, and document storage centers
- Access to GxP computer applications not limited to authorized personnel.
- Sharing of passwords and logon IDs
- Employees logged in to unattended computer terminals.
- No requirements for periodic password updates
Examples of Data Integrity Problems

- Lack of employee ownership and accountability
  - Improper data manipulation
  - Adjustment of time clocks
  - Backdating of information
  - Creating records after the fact
  - Excluding adverse information
  - Discarding or destroying original records

- Data systems not accurate, reliable, nor fit for their intended use.
  - Uncontrolled or haphazard backup/restore, copying, and archiving of data
  - No review of electronic record by supervisory personnel
  - Audit trails not maintained nor reviewed
  - Poor process flow inhibits access to documentation systems
  - Floor operators lack access to document process exceptions
Recent FDA Inspection Findings

- **Poor Documentation Practices**
  - Batch records found in the trash which don’t match “official” records
  - Photocopied labels with information filled out in advance of activity occurring
  - Data recorded for a microbial test with no sample plates found in the incubator
  - Microbial contamination recorded in an unofficial notebook but not found in any GMP documentation
  - Lack of second person verification of data

- **Poor laboratory practices.**
  - Manipulation of integration settings to achieve passing results
  - Retesting samples outside the quality system until a passing result is achieved.
  - Using multiple “trial/setup/training injections” before recording a single result.
  - Use of analytical methods not validated
  - Results can not be reproduced on subsequent aliquots

- **Security Breaches of physical plant or information systems**
  - Using Administrator access to override analyst results
  - Deletion of raw data or unfavorable results
  - Inspector denied access to view data recorded on a thumb drive
Elements of a Data Integrity Program

- Personnel and Training
- Validation Program
- Security
- Audits
- Data Review and Audit Trails
- Governance
- Data Integrity Findings and Investigations
- Corrective and Preventive Actions (CAPAs)
Data Governance

Management should develop and implement a Data Governance System to ensure Data Integrity principles, requirements, definitions and supporting processes are clearly defined, and that Data is managed in accordance with applicable regulations, guidance and best practice throughout the Data Lifecycle.

Risk management principles should be applied when developing and assigning resources for Data Governance, ensuring an acceptable level of control is in place based on the criticality and risk to data.
Data Governance: Key Attributes

• Management should be responsible for the design, implementation, monitoring and maintenance of the data governance system to ensure systems and processes are compliant with data integrity requirements and principles.
• Appropriate resources should be in place to demonstrate support for the data governance system, and to ensure compliance with data integrity principles, procedures, and applicable regulations.
• Roles, responsibilities and the ownership of data should be established throughout the data lifecycle.
• Procedures and controls should be established to ensure data integrity, including such that define accountability for individuals who breach such requirements.
Data Governance

- Effective process and product monitoring provide early warning of emerging quality issues.
- Training should be established in data integrity principles, elements and practices for all individuals responsible for data in the testing and manufacturing of drug product.
- Data integrity issues should be communicated and/or escalated commensurate with criticality – to include establishing appropriate timelines to address Data Integrity compliance gaps.
- Data integrity principles should be applied to outsourced activities, including contract givers and suppliers.
- Self inspection should include a review of the effectiveness of the data governance system.
Quality Culture

• Management controls should be established, communicated and followed to:
  • Promote transparency and timely escalation of possible data integrity gaps
  • Provide incentives and amnesty for communication of possible gaps
  • Provide a no-retaliation environment to allow for individuals to raise and investigate concerns without fear of retaliation
Integration

A robust and effective QMS is intended to integrate the objectives and requirements (systems/processes/programs) of GMP regulations and Data Integrity principles throughout the QMS and its associated systems.

Based on FDA’s Six System Inspection Model, the QMS consists of the following systems:

- Quality System
- Production System
- Facilities and Equipment System
- Laboratory Controls System
- Materials System
- Packaging and Labeling System
Indicators of Potential Data Integrity Gaps

- Discrepancies between Workload, Capacity and Output
  - Equipment
  - Materials Management
  - Resourcing
- Quality Metrics show delays in closure of quality records
- Lack of documented deviations/incidents/OOS reports/Data integrity issues
- Separate quality system or laboratories for “other” markets
- Lack of detailed procedures for review of electronic data
- Computerized and automated system risks not well understood/identified and tested to confirm controls and configuration are appropriate
- Documents not submitted to Quality in timely manner (no time limits or monitoring of this timeline)
- Documents found in trash/recycle/shredder bins (location of bins in areas where documents should not need to be discarded)
GMP regulations do not require determining intent while assessing Data Integrity, however companies should determine intent. Even with deliberate falsification of records, companies must understand the dynamics that drove and allowed the individual to do this if companies are to truly fix the issue and prevent its reoccurrence.

Without an understanding of the true root causes for human misbehavior, companies may be forced to take widespread actions that may not be indicated, especially when factored with the preventive data integrity measures already in-place.
<table>
<thead>
<tr>
<th>Malfeasance</th>
<th>Quality Culture &amp; Code of Conduct</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Elements of Code of Conduct for Data Integrity</td>
</tr>
<tr>
<td></td>
<td>✓ Enforcement &amp; Discipline built into CoC</td>
</tr>
<tr>
<td></td>
<td>• Speak-up Culture - Quality Culture Maturity</td>
</tr>
<tr>
<td></td>
<td>✓ Tone at the Top</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sloppiness</th>
<th>Management Controls Elements Built into DI Tech Reports</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>✓ Auditing &amp; Monitoring -</td>
</tr>
<tr>
<td></td>
<td>✓ Accountability &amp; Supervision</td>
</tr>
<tr>
<td></td>
<td>✓ Resource Allocation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ignorance</th>
<th>Knowledge, Training, &amp; Awareness</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Technical Reports</td>
</tr>
<tr>
<td></td>
<td>• Workshops</td>
</tr>
<tr>
<td></td>
<td>• Training program</td>
</tr>
</tbody>
</table>
Data Integrity

What is PDA doing?
Data Integrity Resources

A data integrity program is a system designed to ensure that the data used to demonstrate compliance with regulatory requirements is accurate. The transmission and content of the company’s data are what they are purposed to be.

Data integrity has been and currently is a major global concern of Health Authorities and the pharmaceutical industry. Although not a new issue, numerous recent Health Authority enforcement actions, such as Warning Letters, Import Alerts, Product Detentions and suspension or revocation of Marketing Authorizations, have focused attention on data integrity.

To provide resources that holistically address issues related to data integrity, PDA is developing a comprehensive set of tools for industry that includes a Code of Conduct, Technical Reports and Points to Consider documents, along with

pda.org/dataintegrity
2016 PDA Data Integrity Deliverables: Workshops, Tools & Training Courses

<table>
<thead>
<tr>
<th>Date</th>
<th>Venue</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 19-20</td>
<td>Millennium Gloucester Hotel</td>
<td>London, UK</td>
</tr>
<tr>
<td>Sept 14-15</td>
<td>Renaissance Washington DC, Hotel</td>
<td>Washington, DC</td>
</tr>
<tr>
<td>Nov 8-9</td>
<td>Titanic Chaussee Berlin</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>Dec 7-8</td>
<td>Manchester Grand Hyatt</td>
<td>San Diego, CA</td>
</tr>
</tbody>
</table>

TOOLS AND TRAINING
Root Cause/Risk Assessment Matrix
PDA Education Course
### PDA Data Integrity Deliverables: Publications

<table>
<thead>
<tr>
<th>Publication</th>
<th>Title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Points To Consider</td>
<td>Elements of a Code of Conduct for Data Integrity in Pharmaceutical Industry</td>
<td>Published (&gt;1000 downloads)</td>
</tr>
<tr>
<td>Points To Consider</td>
<td>Fundamental Concepts for Data Integrity</td>
<td>Published</td>
</tr>
<tr>
<td>Book</td>
<td>Assuring Data Integrity for Life Sciences</td>
<td>Published</td>
</tr>
<tr>
<td>Technical Report</td>
<td>Data Integrity in Laboratories Systems</td>
<td>Q3/Q4 2017</td>
</tr>
<tr>
<td>Technical Report</td>
<td>Data Integrity: Integration into QMS</td>
<td>Q3 2018</td>
</tr>
<tr>
<td>Technical Report</td>
<td>Data Integrity in Manufacturing Systems</td>
<td>Q2 2018</td>
</tr>
</tbody>
</table>
Introduction

Data Integrity has been and currently is a major global concern of Health Authorities and the pharmaceutical industry. Although not a new issue, numerous recent Health Authority enforcement actions such as Warning Letters, Import Alerts, Product Detentions, and suspension or revocation of Marketing Authorizations has focused attention on Data Integrity. Data Integrity can result from lack of awareness of regulatory requirements, employee errors, failure to check accuracy of data, software or system malfunction, or configuration problems with electronic data handling, or malfeasance by employees. To holistically address Data Integrity, the Parenteral Drug Association (PDA) is developing a set of tools in the form of PDA Technical Reports, PDA Training Program, Data Integrity Workshops, and Points to Consider documents that can be used by industry to address this serious issue. This document presents the views of the Parenteral Drug Association (PDA) on the benefits for companies to voluntarily adopt a Code of Conduct for assuring data integrity.

How to Use this Document

This document was developed by a team with expertise in the fields of quality, regulatory affairs, auditing, and manufacturing and reviewed by attorneys specialized in food, drug and labor law. This document is written for easy adoption, in part or in its entirety, by companies, if they so choose, without the need for extensive rewriting of the document. Therefore, the terms ‘shall’ and ‘must’ have been used to permit the Code to be enforceable by the company, if adopted. This document is intended to reinforce a culture of quality and trust within the pharmaceutical industry. It is not intended to be a regulatory standard or guidance, nor is it intended to supersede any country specific or local laws and regulations governing labor, privacy and/or employee rights.

In order for the language used below to be as globally applicable as possible, the document scope has been limited to drug and biological medicinal products. The same or similar concepts could be applied for device and combination products manufacturing. PDA is providing this document and these concepts as a service to members and an example of best practices to the pharmaceutical industry. Please see Section 2 below for more details on how to use this code. Section 3 begins the code of conduct provisions.
Elements of a Code of Conduct for Data Integrity

Scope and Purpose

• Developed by a team of quality and regulatory experts with input from attorneys.
• Ready to use language that can be incorporated into existing company codes of conduct or supplier quality agreements.
• Written to apply to GXP activities for drug and biological products.
Key Elements and Sections

• Senior Management must establish quality standards and requirements.
• Every employee has a duty to engage in conduct which results in data that are accurate, truthful and complete.
  • Data Collection, Analysis, Reporting and Retention
  • Electronic Data Acquisition Systems and Access Security
  • Auditing and Investigations
  • Internal Reporting Responsibility and Disciplinary Actions
  • Notifying Regulatory Authorities
  • Outsourced Services and Purchased Raw Materials
  • Employee Training
  • Glossary of Terms
PDA Points To Consider: Fundamental Concepts in Data Integrity

BOB BUHLMANN, a MADLENE DOLE, b and ZENA KAUFMANN a

aDirector, Corporate Quality Assurance, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA; bDI Program Lead and Head of Strategic Planning and Operations Group QA, Novartis; and cConsultant, ZKG Consulting. ©FDA, Inc. 2016

Executive Summary

The purpose of this document is to describe behaviors, including the elements and controls, to ensure the integrity of GxP data in pharmaceutical manufacturing operations. Fundamental concepts such as ALCOA (attributable, legible, contemporaneous, original, and accurate) and the prevent/detect/respond approach to a data integrity program are defined and discussed. This paper was developed through the Parenteral Drug Association (PDA) Data Integrity Task Force and reviewed and approved by the PDA Regulatory and Quality Advisory Board as well as the PDA Board of Directors.

Data integrity is a significant component of a company’s Quality System, providing foundational assurance of the data a company uses to operate in compliance with regulatory requirements and to demonstrate its products are safe and effective for their intended use. Through data integrity the company recognizes its responsibility to prove the origin, transmission, and content of the company’s data and that data is what it is purposed to be. To holistically address Data Integrity, the FDA is developing a set of tools in the form of PDA Technical Reports, PDA Training, Data Integrity Workshops, and Points To Consider documents that can be used by industry to address this serious issue. This document serves as an introduction to that suite of tools to follow.

Purpose

The purpose of this document is to describe behaviors, including the elements and controls, to ensure the integrity of GxP data in pharmaceutical manufacturing operations.

Data integrity is a significant component of a company’s Quality System, providing foundational assurance of the data a company uses to operate in compliance with regulatory requirements and to demonstrate its products are safe and effective for their intended use. Through data integrity the company recognizes its responsibility to prove the origin, transmission, and content of the company’s data and is what it is purposed to be. To holistically address Data Integrity, the Parenteral Drug Association (PDA) is developing a set of tools in the form of PDA Technical Reports, PDA Training, Data Integrity Workshops, and Points To Consider documents that can be used by industry to address this serious issue. This document serves as an introduction to that suite of tools to follow.

The Importance of Data Integrity throughout the Product Lifecycle

Nearly every GxP activity at a company generates some form of data or documentation. GxP regulations require companies to put systems in place to ensure the completeness and accuracy throughout the lifecycle of these records, including, but not limited to:

- Creation and recording
- Processing and transferring
- Use, reporting, replication, and distribution
- Archival, backup, restoration, obsoleting, and retirement

*Corresponding Author: Bob Buhlmann, Director, Corporate Quality Assurance, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799; e-mail: buhlmann@amgen.com

doi: 10.3731/pdajpst.2016.007062
<table>
<thead>
<tr>
<th>Key Elements</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Executive Summary</td>
</tr>
<tr>
<td>• Purpose</td>
</tr>
<tr>
<td>• The Importance of Data Integrity throughout the Product Lifecycle</td>
</tr>
<tr>
<td>• Current Regulatory Trends and Recent Issues in Data Integrity</td>
</tr>
<tr>
<td>• Data Management Systems Considerations</td>
</tr>
<tr>
<td>• Globalization and Cultural Factors</td>
</tr>
<tr>
<td>• Elements of Data Integrity</td>
</tr>
<tr>
<td>• Holistic Approach to a Data Integrity Program through the Data Lifecycle</td>
</tr>
<tr>
<td>• Personnel and Training.</td>
</tr>
<tr>
<td>• Validation Program</td>
</tr>
<tr>
<td>• Security</td>
</tr>
<tr>
<td>• Audits</td>
</tr>
<tr>
<td>• Data Review and Audit Trails</td>
</tr>
<tr>
<td>• Governance</td>
</tr>
<tr>
<td>• Data Integrity Findings and Investigations</td>
</tr>
<tr>
<td>• Corrective and Preventive Actions (CAPAs)</td>
</tr>
<tr>
<td>• Conclusion</td>
</tr>
</tbody>
</table>

Connecting People, Science & Regulation®

Copyright © PDA 2017
Executive Summary

• The purpose of this document is to describe behaviors, including the elements and controls, to ensure the integrity of GxP data in pharmaceutical manufacturing operations. Fundamental concepts such as ALCOA (attributable, legible, contemporaneous, original, and accurate) and the prevent/detect/respond approach to a data integrity program are defined and discussed. This paper was developed through the Parenteral Drug Association (PDA) Data Integrity Task Force and reviewed and approved by the PDA Regulatory and Quality Advisory Board as well as the PDA Board of Directors.
Data integrity is a significant component of a company’s Quality System, providing foundational assurance of the data a company uses to operate in compliance with regulatory requirements and to demonstrate its products are safe and effective for their intended use. Through data integrity the company recognizes its responsibility to prove the origin, transmission, and content of the company’s data and that data is what it is purported to be. To holistically address Data Integrity, the PDA is developing a set of tools in the form of PDA Technical Reports, PDA Training, Data Integrity Workshops, and Points To Consider documents that can be used by industry to address this serious issue. This document serves as an introduction to that suite of tools to follow.
Data Integrity Task Force: Expected Outcomes

• Harmonized standards to comply with regulatory expectations for maintaining data integrity,
• Defining mechanisms for detecting non-compliance and outlining a clear methodology for remediating gaps.
• Serves both industry and regulators in creating and defining solutions for the increasing number of failed inspections where firms lack the needed controls to ensure data integrity and lack the expertise to detect and resolve non-compliance
• Methodology for restoring confidence in a system and organization to avoid revenue loss and regulatory impacts.
Acknowledgements

• Anil Sawant, J&J and the PDA Data Integrity Task Force

• Maryann Gribbin
  – Chief Compliance Officer, Faith & Royale Consultants
  – Co-Chair PDA Data Integrity Task Force
Questions?

• Richard M. Johnson
• E: johnson@pda.org
• P: +1.301.656.5900

More Info.:

https://www.pda.org/scientific-and-regulatory-affairs/regulatory-resources/data-integrity